Cart
sales@molnova.com
BMS-684
CAS No. 313552-29-3
BMS-684( —— )
Catalog No. M37108 CAS No. 313552-29-3
BMS-684 is a selective and potent DGKα inhibitor (IC50: 15 nM) with potential antitumor activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 201 | In Stock |
|
| 5MG | 312 | In Stock |
|
| 10MG | 502 | In Stock |
|
| 25MG | 778 | In Stock |
|
| 50MG | 1040 | In Stock |
|
| 100MG | 1377 | In Stock |
|
| 500MG | 2673 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBMS-684
-
NoteResearch use only, not for human use.
-
Brief DescriptionBMS-684 is a selective and potent DGKα inhibitor (IC50: 15 nM) with potential antitumor activity.
-
DescriptionBMS-684 is a selective DGKα inhibitor with an IC50 of 15 nM. BMS-684 inhibits DGKα kinase activity with >100-fold selectivity over the related DGK type I family members DGKβ and DGKγ. BMS-684 does not inhibit any of the other seven DGK isozymes.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number313552-29-3
-
Formula Weight454.52
-
Molecular FormulaC27H26N4O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C1C([N+]([O-])=O)=C(N2CCN(C(C3=CC=CC=C3)C4=CC=CC=C4)CC2)C5=C(N1C)C=CC=C5
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Michael Wichroski, et al. DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell-mediated antitumor immunity. Sci Transl Med. 2023 Oct 25;15(719):eadh1892. ?
molnova catalog
related products
-
Isohemiphloin
Isohemiphloin is a flavonoid isolated from Abrus precatorius Linn.
-
WAY-606376
WAY-606376 is an active molecule [often used in pharmaceuticals] with potential therapeutic applications.
-
CGS 20625
CGS 20625 is an orally active, specific, and potent partial agonist at the central benzodiazepine receptor with anxiolytic and anticonvulsant activity.
